Physician profile
Akshat Jain
NPI 1700150885
$447,093.73
in general payments reported to CMS, 2019-2025
23 companies · $223K in 2025
The $223K reported for 2025 was more than what 99% of Pediatric Hematology-Oncology providers received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,705 · 2020: $27K · 2021: $17K · 2022: $20K · 2023: $63K · 2024: $90K · 2025: $223K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $240K · Consulting Fee: $76K · Travel and Lodging: $47K · Honoraria: $6,400 · Food and Beverage: $5,927 · Education: $16.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $240,309.32 |
| Consulting Fee | $76,180.90 |
| Travel and Lodging | $46,860.13 |
| Honoraria | $6,400.00 |
| Food and Beverage | $5,926.70 |
| Education | $16.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $181,364.03 | 2022-2025 | |
| Pfizer INC. | $91,156.16 | 2021-2025 | |
| Novo Nordisk INC | $75,384.12 | 2022-2025 | Alhemo, Novoseven, Esperoct |
| Octapharma USA, INC. | $24,422.46 | 2020-2025 | Nuwiq, Fibryga & Balfaxar, Wilate - Von Willebrand Factor/Coagulation Factor Viii Complex (Human) |
| Takeda Pharmaceuticals U.S.A., INC. | $18,130.00 | 2020-2022 | |
| Sanofi US Services INC. | $14,717.50 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $13,690.67 | 2019-2025 | |
| Global Blood Therapeutics, INC. | $7,918.84 | 2020-2022 | |
| Csl Behring | $6,527.90 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $4,556.05 | 2019 | |
| Dova Pharmaceuticals | $3,080.00 | 2021 | |
| Shire North American Group INC | $2,030.95 | 2019 | |
| Bioverativ Therapeutics INC. | $1,953.75 | 2019-2021 | |
| Cerus Corporation | $594.89 | 2019 | |
| Novo Nordisk Health Care Ag | $375.00 | 2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardinal Health 110 LLC | $300.00 | 2024 | |
| Agios Pharmaceuticals, INC. | $228.61 | 2022-2024 | Pyrukynd |
| Jazz Pharmaceuticals INC. | $150.00 | 2024 | |
| Biomarin Pharmaceutical INC. | $136.47 | 2024 | |
| Novartis Pharmaceuticals Corporation | $134.09 | 2019 | |
| Genentech, INC. | $119.85 | 2019 | |
| Genentech USA, INC. | $80.39 | 2025 | Hemlibra |
| Vertex Pharmaceuticals Incorporated | $42.00 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Akshat Jain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.